title: Reply to 'Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents' by Saad and Buyse.
authors.affiliation: Department of Medical Oncology, Admiraal de Ruyter hospital, Goes, The Netherlands h.vanhalteren@adrz.nl.
authors.forename: H K
authors.initials: HK
authors.lastname: van Halteren
mesh_terms: D000970:Antineoplastic Agents; D017277:Drug Approval; D006801:Humans
chemical_list: D000970:Antineoplastic Agents